Fulvestrant

Catalog No.S1191 Synonyms: ICI-182780, ZD 9238

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • PTPH1 confers breast cancer cell sensitivity to fulvestrant. E and F, PTPH1 overexpression increases the growth inhibition by fulvestrant. PTPH1 was overexpressed by a Tet-on system or a stable transfection, and resultant cells were incubated with fulvestrant as indicated for about 2 weeks. Colony formed was stained and counted. Results shown are normalized to its own solvent control of Vector and PTPH1-overexpressed cells, respectively (means ± SD; n = 3–5) with insets showing PTPH1 overexpression. *, versus vector or no Tet cells for E and F.

    Mol Cancer Ther 2014 13(1), 230-8. Fulvestrant purchased from Selleck.

     

    Fulvestrant resistance induced by 6 different ZF-TFs. (A) Drug sensitivity of fulvestrant-selected MCF7 ZF-TF-transduced cells. MCF7 cells transduced with one of six different ZF-TF-expressing retroviruses selected first in puromycin (the transduction selection marker) and then in fulvestrant for 1 month were grown in the absence of fulvestrant for 7 days and then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for 21 days followed by crystal violet staining and visualization. Data are representative of triplicate experiments.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

  • Fulvestrant resistance induced by 6 different ZF-TFs. (B and C) Growth curves of MCF7 and T47D cells in the presence and absence of fulvestrant. Comparison of cell growth rates (cell number, mean +/2 SEM, n = 8; time in days as indicated) of MCF7 and T47D cells stably transduced with control retrovirus or one of six different ZF-TF-expressing retroviruses (7, 19, 64, 70, 83 and 115) in the presence (blue line) or absence (pink line) of fulvestrant.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

    CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments. (c) MCF-7 and MR cells were treated with different concentrations of ICI, collected after 24 h and then immunoblotted with the indicated antibodies.

    Oncogene, 2016. Fulvestrant purchased from Selleck.

  • A: Time dependent loss of MGMT activity in ERα-positive MCF7 and T47D tumor cells but not in ERα-negative MDAMB-468 cells after 1 μmol/L Fulvestrant treatment (upper panel). Concentration dependent inhibition of MGMT activity in MCF7 and T47D cells but not in MDA-MB-468 cells after a 72 hours exposure to fulvestrant (lower panel). The data represents the mean of two independent experiments in duplicate and the last time point (72 hours) as assessed by student's t-test was significant at P < 0.05. B: Decreased MGMT and ER-α protein levels in MCF7 cells after 48 hours and 72 hours fulvestrant exposure. ICI is fulvestrant, also called ICI-182,780. C: Decreased MGMT and ER-α protein levels in T47D cells after 48 hours and 72 hours fulvestrant exposure.

    J Biomed Res, 2016, 30(5):393-410. Fulvestrant purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.
Targets
ER [1]
(Cell-free assay)
0.94 nM
In vitro

Fulvestrant is an effective inhibitor of the growth of ER-positive MCF-7 (with IC50 of 0.29 nM) but with no effect on the growth of ER-negative BT-20 human breast cancer cells. Fulvestrant causes accumulation of cells in G0/G1 and also reduces the proportion of cells capable of continued DNA synthesis. [1] Fulvestrant competitively inhibits binding of oestradiol to the estrogen receptor. Fulvestrant blocks nuclear localization of the ER through impairing receptor dimerisation, and energy-dependent nucleo-cytoplasmic shuttling. Because of the instability of fulvestrant-ER complex, the binding of Fulvestrant with ER finally results in accelerated degradation of the ER protein. [2] Fulvestrant (10 nM) not only decreases IGF-IR mRNA levels but also decreases the half-life. [3] Treatment with 100 μM Fulvestrant leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. [4] Fulvestrant is capable of down-regulating androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Fulvestrant also significantly attenuates R1881-stimulated growth by 70%. [5] Fulvestrant is able to modulate mitosis and cell death in immature cerebellar neurons via rapid activation of MAPK. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV33cVcxOS5|LUGwNFAhdk1? MkO0OFghcA>? MkexbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHnBRZYzPDl5OUK5OC=>
MCF-7/LTED NIPufZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHBNU4{NTFyMECgcm0> M{jqO|Q5KGh? MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFnkdZAzPDl5OUK5OC=>
HCC1428 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzCZ5lROS5|LUGwNFAhdk1? NH;LN3o1QCCq M3jWRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHvvdlgzPDl5OUK5OC=>
HCC1428/LTED MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzkfHlCOS5|LUGwNFAhdk1? M{TENVQ5KGh? NInKRXlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYfkeJRoOjR7N{myPVQ>
LCC1 MYXGeY5kfGmxbjDBd5NigQ>? M1rPc|ExOCCwTR?= MYe0PE0yPDRiaB?= M{j0WYFkfGm4YYTld{BWWFJic3nncoFtcW6p NVLOZnl7OjR6NUiyO|c>
LCC9 NUfEcYJKTnWwY4Tpc44hSXO|YYm= M2qzUVExOCCwTR?= NHvHSVg1QC1zNESgbC=> MXThZ5RqfmG2ZYOgWXBTKHOrZ37hcIlv\w>? M3TWZ|I1QDV6Mke3
MCF-7  NVvpO3RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfINVAxKG6P NUfBdY1CPSCm NUP4cphRcW6qaXLpeJMh[2WubDDndo94fGhidH:gNVDwxIV? M3TJVFI1QDF7NUWw
mesangial  MX7GeY5kfGmxbjDBd5NigQ>? MkTrNE4yNTFyMDDuUS=> NECwWWE1QCCq M170ZZN2eHC{ZYPz[ZMhXEeILd8yNU1qdmS3Y3XkJJR6eGViSW[gZ49tdGGpZX6= NHXGOYkzPDd7M{[zPS=>
Mesangial M4jKT2Z2dmO2aX;uJGF{e2G7 M{PkSVAvOS1zMECgcm0> NHvlVY0xNjViaB?= MY\pcohq[mm2czDUS2Yu|rJzLXnu[JVk\WRiU33h[FIheGixc4Doc5J6dGG2aX;uJJZq[SCJUFXS MYqyOFc6OzZ|OR?=
ER+ MCF-7/2a MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz6XZpKSzVyPUCuNFA1KM7:TR?= MUKxOVMzPDh6NB?=
ER+ MCF-7 M{e5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLZbm1bOjByIHi= MlrITWM2OD1yLkKxJI5O M{TRelE2OzJ2OEi0
MCF-7  NYXa[GV5TnWwY4Tpc44hSXO|YYm= MWexNOKhdk4EoB?= NF;PR5c4OiCq NI\VNGtz\X[ncoPld{B1cGViZYP0do9o\W5iZX\m[YN1MEmFNUCgNU46KMPZIEGw5qiTQSCPKR?= NHPiVIEzPDlyOE[1Ni=>
MCF-7  NYfo[XEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxyqCxZjDhdJBzd3irbXH0[Yx6KDJibl2= MoHpNlM1PDh|NE[=
H1975  NHPk[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfiN:Kh|ryP M3jqcFEhdQ>? NXHNRVY2cW6lcnXhd4V{KHSqZTDn[YZqfGmwaXKgd4Vve2m2aY\peJkhd2ZiSEG5O|Uh[2WubIRCpC=> MmHqNlQzPjh6MUC=
H1975 MlXBSpVv[3Srb36gRZN{[Xl? MmO1N:Kh|ryP M33sbFEhdQ>? NILIOVl2eHKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gUIV1NTel NH;NVnIzPDJ4OEixNC=>
MCF-7  M{i3c2Z2dmO2aX;uJGF{e2G7 M2r6bFExOOLCiX7NxsA> MkT6O|IhcA>? M1HrPZJmfmW{c3XzJJRp\SCycn;0[YN1cX[nIHXm[oVkfCCxZjDFNuKhcW5iY3XscEBqdn[jc3nvci=> MnGxNlM6OzZ5N{O=
MCF-7  MXXGeY5kfGmxbjDBd5NigQ>? M4fjcVExOOLCiX7NxsA> MoPoNlQwPDhiaB?= M1LnfIZi[2muaYTheIV{KGmwdnHzbY9vKHSqcn;1[4ghVU2SczegcY9lfWyjdHnvci=> NEPCfGMzOzl|Nke3Ny=>
BT474-tet-shMED1 NVTyUHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTFNE4yNTVizszN M{K0Nlch\A>? M1nlO4lv[3KnYYPld{AsTG:6IHnu[JVk\WRiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3nue|I{QTN4MkO0
ZR75-1-tet-shMED1  NFu1emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuwMlEuPSEQvF2= NEDZZnU4KGR? NFvXTXhqdmO{ZXHz[ZMhM0SxeDDpcoR2[2WmIHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1rUU|I{QTN4MkO0
MCF-7-tet-shMED1 M3HXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInwWnUxNjFvNTFOwG0> NFrqU5E4KGR? M1v4U4lv[3KnYYPld{AsTG:6IHnu[JVk\WRiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGixXmozOzl|NkKzOC=>
HepG2  Mnr2SpVv[3Srb36gRZN{[Xl? M{DMNlAvODFvMUCg{txO NWnPOYtrOThiaNMg NFjNZ|Ji[3SrdnH0[ZMhfGinIFXSSU1u\WSrYYTl[EB1emGwc3PybZB1cW:wIH;mJGFHOkWU MXGyN|c{OzF6OB?=
MCF-7L  NHXEOmxHfW6ldHnvckBCe3OjeR?= NV;xc|FKOTByIH7NxsA> NInZXHYyOCCvaX6vNlQhcC92ODDo MlXpdoV{fWy2czDpckBGT0[ULDDISXIzKGGwZDDISXI{KHCqb4PwbI9zgWyjdHnvckBifCCycn;sc45o\WRiZYjwc5N2emV? Ml3qNlM3QDZ2MU[=
MCF-7L  NF\2OIZHfW6ldHnvckBCe3OjeR?= MofHNVAxKG6PwrC= NEDJd4w1QCCq NXLKSW1tcW6mdXPld{B2eHKnZ4XsZZRqd25ib3[gcXJPSSCxZjDFS2ZTKGyrZ3Hu[EBJSi2HR1[= NELOfXQzOzZ6NkSxOi=>
MCF-7L NWDTTZhCTnWwY4Tpc44hSXO|YYm= MX[xNFAhdk4EoB?= Ml7aOFghcA>? NFy1NmtqdmS3Y3XzJGVITlJiZnHtbYx6KG2nbXLldkBi[3SrdnH0bY9vKHKncYXpdoVlKEWU MYWyN|Y5PjRzNh?=
C4-12  NWrFcWxNTnWwY4Tpc44hSXO|YYm= NUK4bmNKOTByIH7NxsA> MUG0PEBp MVPpcoR2[2W|IFXHSnIh\mGvaXz5JI1mdWKncjDhZ5RqfmG2aX;uJJJmeXWrcnXkJGVT NEjFTpgzOzZ6NkSxOi=>
MCF-7L NEC5[o5HfW6ldHnvckBCe3OjeR?= NEf2NVMyODBibl5CpC=> NILJN2UzPCCq MnGxbY5lfWOnczDFS2ZTKHCqb4PwbI9zgWyjdHnvckBz\XG3aYLl[EBJSi2HR1[g[pVv[3Srb36= NXrnbYY2OjN4OE[0NVY>
MMQ  MmP3SpVv[3Srb36gRZN{[Xl? MYCwMVYzPSCwTR?= M33BZVczKGh? MWDkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCnc4Tyc4dmdiC{ZXPldJRwei4QsTCoSXLPuSl? NW[5Vo5KOjN3MkOzOVc>
H1975  NELzfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULVPWxsOC5|MUK1MVExKM7:TR?= NV61c5Q1PiCm M{nnPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVKyN|M6QTl3Nx?=
H1975  NWLFXoMxSXCxcITvd4l{KEG|c3H5 MUGyNFAhdk1? MkPzO|IhcA>? NGDZcIJmdmijbnPld{BmemyxdHnubYIhcW6mdXPl[EBieG:ydH;zbZM> NWXjWpM1OjN|OUm5OVc>
MCF-7  MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmxNE8yODBxMUCwNEBvVQ>? NEjibFkzNzRxNjDk MWDEUXNQ NUjHXY84cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NG\vZmMzOzNzM{WwOi=>
MCF-7  M2XTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVyxNFAhdk1? M1XGelQh\A>? Ml;KSG1UVw>? MVTpcoR2[2W|IHGgbIlocGW{IIDyc5BwenSrb36gc4Yh[2WubIOgbY4hfGinIFexJJBp[XOnwrC= NXL1PYI4OjN|MUO1NFY>
MLO-Y4  M3Hid2Z2dmO2aX;uJGF{e2G7 MW[xxsDPxE1? NXPreHFxOSCq NHLZVlFqdmirYnn0d{BGOi2rbnT1Z4VlKEO6NEOg[ZhxemW|c3nvci=> MUiyN|I1PzB3Nx?=
MCF-7 NUHne|Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzaNVAxKG6P NYrwOXdlPDhiaB?= NYi5dWRD[WK{b3fheIV{KHSqZTDwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCvb3TldoF1\SCwaYTyc5NifGm4ZTDzeJJme3N? NH7PdpAzOzJzNke0OC=>
TG1-1  Ml;DSpVv[3Srb36gRZN{[Xl? NVra[nZpOcLizszN NYTsbYNoOjRiaB?= M3v2b4Fjem:pYYTld{BGOsLiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhUEmILUJOtS=> Mk\HNlMxQDh4MEe=
TG1-1  MlPySpVv[3Srb36gRZN{[Xl? M17WZ|HDqM7:TR?= M{LLc|I1KGh? MVXhZpJw\2G2ZYOgSVLDqGmwZIXj[YQh[WOldX31cIF1cW:wIH;mJHBKO0t? NIDC[GIzOzB6OE[wOy=>
MCF7 NVOwOI52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn0N3B1OTByIH7N NVf2WlBtPDhiaB?= M3Laboxm[WS|IITvJIEhe2mvaXzhdkBtd3O|IHnuJJN2en[rdnHsJIF{KHerdHig[I95d3K3YnnjbY4h[WyxbnW= NYXxWol2OjNyN{eyOFk>
MCF7 NH7FTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnLVpg2OTByIH7N M{fvbVQ5KGh? MWDlcohidmOnczDueZRtcW5vbXXkbYF1\WRiY3XscEBl\WG2aB?= MUWyN|A4PzJ2OR?=
MCF-7  MkSxSpVv[3Srb36gRZN{[Xl? NYrLb3VrPiCq M1OwcWROW09? NU\VZlRT[XS2ZX71ZZRmeyC2aHWg[ox2\GmxeH;ubYwuKG:{IH\lcohmgGGvaXStbY5lfWOnZDDpcoNz\WG|ZTDpckBucVJvMkGg[ZhxemW|c3nvci=> MUiyN|A2OjB|Nh?=
MCF-7 NXH5cnpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf2eFF7OTByIH7NM|Eh|ryP NVnsT|JRPSCm MljYbY5pcWKrdIOgeIhmKHO2aX31cIF1cW:wIH;mJFE4|rJvZYP0doFlcW:u M33yWFIzQTh{N{[1
MCF-7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT3NVAxKG6P M1PI[lUh\A>? MXHpcohq[mm2czD0bIUhe3SrbYXsZZRqd25ib3[g[pV{[XKrZXzpckBJ NGPJbXozOjl6Mke2OS=>
1471.1 NHi2d2VHfW6ldHnvckBCe3OjeR?= NXXzO5V1OTByIH7N NFPGd48yKGh? M3;3[GV1V0kEoB?= M1;Y[ZRic2W|IH;uJIEheHWwY4TheIUhe3SjaX7pcocheGG2dHXyci=> NWnUbFZMOjJ6NkmxNFY>
MCF-7 NWHyfZRlTnWwY4Tpc44hSXO|YYm= MWKxNFAhdk1? MXGxJIg> NXvuW4ZsTXSRSNMg NIjXc5p1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NHH6THczOjh4OUGwOi=>
HeLa NIDiSnNHfW6ldHnvckBCe3OjeR?= Ml22NVAxKG6P MmX2NUBp NYDBWmc4TXSRSNMg NX;oOIs5fGGtZYOgc44h[SCydX7jeIF1\SC|dHHpcolv\yCyYYT0[ZJv M3vOR|IzQDZ7MUC2
COS-7  M1;rcGZ2dmO2aX;uJGF{e2G7 M4jQVlExOCCwTR?= NHm4c|gyKGh? M1vu[2V1V0kEoB?= Mn;ZeIFs\XNib36gZUBxfW6ldHH0[UB{fGGrbnnu[{Bx[XS2ZYLu MnHMNlI5PjlzME[=
BG1L-OHTLT  MUPGeY5kfGmxbjDBd5NigQ>? M2DpPVExyqCwTR?= MWiyOOKhcMLi NUC4THFjcW6qaXLpeJMhTVMQsTDlfJBz\XO|aX;u NXPabVhLOjJ4NUK1OVg>
BG1L-ICILT NXv5R4Y2TnWwY4Tpc44hSXO|YYm= MXOxNOKhdk1? NHLxSZozPMLiaNMg MX\pcohq[mm2czDFVu6yKGW6cILld5Nqd25? MmjCNlI3PTJ3NUi=
PC-9 NWj5TYdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCwMlAxOy1|MDFOwG0> M1PMZ|Q5KGh? MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmfvNlI2PjB4M{S=
H1650 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j5V|AvODB|LUOwJO69VQ>? MU[0PEBp MoThbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mo\xNlI2PjB4M{S=
H1975 NFXzOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWwMlAxOy1|MDFOwG0> MYO0PEBp NF\IVotqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXWyNlU3ODZ|NB?=
H1975 MXPGeY5kfGmxbjDBd5NigQ>? MoniN:Kh|ryP M2\yPVMhcA>? MoriZYJzd2ejdHXzJJRp\SCyaH;zdIhwNUWJRmKgbY5lfWO2aX;uJIJ6KGW|dILv[4Vv NUG4cXhCOjJ3NkC2N|Q>
H1975 NVe5[HpUTnWwY4Tpc44hSXO|YYm= NYDmeYJRO8LizszN MXy3JIQ> MlT2bY5lfWOnczDFS2ZTKGW6cILld5Nqd25? NFXndWszOjV4ME[zOC=>
HTR-8 NFr4N4pHfW6ldHnvckBCe3OjeR?= M3vNRVHDqM7:TR?= MVSxMVQ5KGh? M4noVYRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyCvUl7B MWCyNlM5OzFzMR?=
JEG-3 NXr2NFcxTnWwY4Tpc44hSXO|YYm= MnXvNeKh|ryP M{jEb|EuPDhiaB?= MnjD[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSVfGRnA4KG2UTlG= NXrvc3RYOjJ|OEOxNVE>
Huh7 NFm4NZpHfW6ldHnvckBCe3OjeR?= MkGzOVDDqM7:TR?= NIf5SYo1QCCq NHzFTW9qdmirYnn0d{Bo\W6rc4TlbY4udWWmaXH0[YQhWE:QMTD0doFve2GldHn2ZZRqd25? NI\jclQzOjNyNEK5Oi=>
201T M4[2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW2OUDPxE1? Mk\qO|IhcA>? NWDpe45VcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= MW[yNlI2QDR5Nh?=
A549  MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXO1JO69VQ>? NYS0R251PzJiaB?= NFvRNJlqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhidnHu[IV1[W6rYh?= NHmxPGIzOjJ3OES3Oi=>
MCF-7 NUfXW3ZDTnWwY4Tpc44hSXO|YYm= NV7OXnpXOcLizszN MnPoNlQhcMLi NV3aNXJF\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi NFHu[W0zOjB2OUOxOi=>
HCC-1428 M2DPOWZ2dmO2aX;uJGF{e2G7 M1\XXVHDqM7:TR?= M1\oVlI1KGkEoB?= NYfGZXdx\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi NHjXSY8zOjB2OUOxOi=>
MDA-361 MWXGeY5kfGmxbjDBd5NigQ>? M3fEclHDqM7:TR?= M4jJ[FI1KGkEoB?= Mlrp[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhPC2RSD3UJOKh MWeyNlA1QTNzNh?=
ZR75-1 MXzGeY5kfGmxbjDBd5NigQ>? MYSxxsDPxE1? NIfCVYMzPCCqwrC= Mni4[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhPC2RSD3UJOKh MkntNlIxPDl|MU[=
MCF-7 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV72N4ZFOcLizszN M1PldFUuOTBiZB?= NE[2c|d{fXCycnXzd4V{KEV{LXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25? NELG[3IzOjB2OUOxOi=>
HCC-1428 NYDiTXNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrpbo0yyqEQvF2= Mki4OU0yOCCm Morpd5VxeHKnc4Pld{BGOi2rbnT1Z4VlKGe{b4f0bEBqdmirYnn0bY9v NW[wTWZyOjJyNEmzNVY>
MDA-361 NWnmOnN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr1PWYyyqEQvF2= NFnTfpc2NTFyIHS= NGLPfnB{fXCycnXzd4V{KEV{LXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25? MUmyNlA1QTNzNh?=
ZR75-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPv[ncyyqEQvF2= MnXLOU0yOCCm MVjzeZBxemW|c3XzJGUzNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> MXWyNlA1QTNzNh?=
MCF-7/AC-1 NUP2[WVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nqclAuOC5{IN88US=> Mk\BOkBl MoDDbY5pcWKrdIOgZ4VtdCCpcn;3eIghdW:mZYP0cJk> Mm\GNlIxPDJ5OUK=
MCF7 M3THcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfveGJmOTBiwsXN MojwOFghcA>? Mk\qbY5lfWOnczDj[YxtKGmwaHnibZRqd25id3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KG[rYoLvZoxie3S| NYr6S24{OjJyNEG4PFc>
MMQ NHnZNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq3N4cxNTZ{NTDuUS=> NXLtVnF1PzJiaB?= NXjVZWRGeHKxZIXj[ZMhe3SjdHnzeIlk[WyueTDzbYdvcW[rY3HueEBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbtMg NUP6OY5SOjJyMUWxNFE>
MMQ MV7GeY5kfGmxbjDBd5NigQ>? NE\5VnAxNTZ{NTDuUS=> M3v2[|czKGh? M{nDN5Bzd2S3Y3XzJIEhe3SjdHnzeIlk[WyueTDzbYdvcW[rY3HueEwh\G:|ZT3k[ZBmdmSnboSgdoVlfWO2aX;uJIlvKFCUTDDz[YNz\XSrb36= MVKyNlAyPTFyMR?=
MCF7 NX;SR41VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnlVGRZOC1zIN88US=> NV7td5JHOjRvMUKwJIg> NFv3SmpqdmirYnn0d{B1cGViZ4Lve5RpKG:oIF3DSlcuYUJvMdMg MUGyNVg3OzJ3OB?=
HepG2 MWrBdI9xfG:|aYOgRZN{[Xl? NFLvbXcxNjIEoN88US=> MmXFNlQhcA>? Ml;sZYJwdGm|aHXzJJRp\SCnc4Tyc4dmdi2rbnT1Z4VlKHWyLYLl[5Vt[XSrb36gc4Yh[XCxQVmgZY5lKGGyb12= MkXINlE5OTZ{M{O=
MCF7–iFR3 NFTUTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGyNE0yODBibl2= MXe5OkBp MnW0[Y5p[W6lZYOgRXAucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w MVWyNVc6Ojh6OR?=
MCF7S NU\VXFNyTnWwY4Tpc44hSXO|YYm= MVixxsDPxE1? NYjJ[3BZPDhiaB?= M2j5ZYRwf26{ZXf1cIF1\XNib4\ldoFtdCCHUt8xJJBzd3SnaX6gcIV3\Wy| MUeyNVU{OzF7NR?=
MCF7 NWjTXmRWTnWwY4Tpc44hSXO|YYm= MV2xxsDPxE1? MnP1OFghcA>? MWrkc5dvemWpdXzheIV{KG:4ZYLhcIwhTVMQsTDwdo91\WmwIHzleoVtew>? M3WwRVIyPTN|MUm1
MCF7S NXr5VpA6TnWwY4Tpc44hSXO|YYm= MXexxsDPxE1? M2rySFch\A>? NFrMXYRifHSnboXheIV{KHS3bX;yd5Bp\XKnIH\vdo1ifGmxbjDhcoQheHKxbHnm[ZJifGmxbh?= MUmyNVU{OzF7NR?=
MCF7S M4HlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHoNE42NzFizszN M1r2Zlch\A>? NVvTdHQ2TE2VTx?= M2fReYRm[3KnYYPld{Bk\WyuIHX4dIFve2mxbh?= MUKyNVU{OzF7NR?=
T47D  NF3GeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPSWoo1KG6P M{D5b|QxKGh? NV:0[Gl{e3WycILld5NmeyClZXzsJIdzd3e2aDDtc4RmemG2ZXz5 NGD5R|IzOTR6MEO5NS=>
BT474  NYfQN|ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjFUpE3PCCwTR?= M1LPdlQxKGh? NFn6epZ{fXCycnXzd4V{KGOnbHyg[5Jwf3SqIH3v[IVz[XSnbIm= M3G1O|IyPDhyM{mx
T47D  M2X4bmZ2dmO2aX;uJGF{e2G7 NWnKWpptOTBibl2= NEC4RXE1OCCq NF6z[Ylld3ewcnXneYxifGW|IFXS{tEheHKxdHXpci=> NVTjVY9pOjF2OECzPVE>
BT474  MoHuSpVv[3Srb36gRZN{[Xl? NYjHWVZ3OTBibl2= NXjscVBsPDBiaB?= NIjsUmlld3ewcnXneYxifGW|IFXS{tEheHKxdHXpci=> NVfCUFNWOjF2OECzPVE>
MCF7 M4H3TWZ2dmO2aX;uJGF{e2G7 MWKxNFAhdk1? NFjuZWQ4KGR? M4nxfJJm\HWlZYOgSXLPuSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> MoXXNlE{QTZyOUS=
T47D  MXTGeY5kfGmxbjDBd5NigQ>? MWSxNFAhdk1? NVG1dWd[PyCm NV:4NHlCemWmdXPld{BGWs7zIHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? M2DUZVIyOzl4MEm0
BT474  MnjZSpVv[3Srb36gRZN{[Xl? NVW3bVFwOTByIH7N MWe3JIQ> NVq3OGZYemWmdXPld{BGWs7zIHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? NFH2NYIzOTN7NkC5OC=>
MDAMB361 MX;GeY5kfGmxbjDBd5NigQ>? MoHFNVAxKG6P NEfGOXo4KGR? NGDZbYtz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 MmqxNlE{QTZyOUS=
MCF7 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWewMlAyNTFizszN NE\tZ4g4KGR? MV\y[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? MlrONlE{QTZyOUS=
T47D  M1TPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j4ZVAvODFvMTFOwG0> NXjXUJNqPyCm NYnYTZptemWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 MXGyNVM6PjB7NB?=
BT474  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\IU24xNjBzLUGg{txO NVfLcVl4PyCm M2jCfpJm\HWlZYOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= MVSyNVM6PjB7NB?=
MDAMB361 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnBSY0xNjBzLUGg{txO M1K4Nlch\A>? NXzlNHFEemWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NUTydmRnOjF|OU[wPVQ>
MCF7 MmT6SpVv[3Srb36gRZN{[Xl? M3fsW|ExOCCwTR?= M3zHc|ch\A>? NHfab|NqdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n NGLxbYkzOTN7NkC5OC=>
T47D  NXTvV|doTnWwY4Tpc44hSXO|YYm= MlLxNVAxKG6P MYC3JIQ> NG\TcWhqdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n MojjNlE{QTZyOUS=
BT474  NYXS[WlvTnWwY4Tpc44hSXO|YYm= MoLWNVAxKG6P MWC3JIQ> NIrJO5VqdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n Mn7aNlE{QTZyOUS=
MDAMB361 MmqzSpVv[3Srb36gRZN{[Xl? M1LPcVExOCCwTR?= MYq3JIQ> NVf3PGFLcW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> NFzLXJYzOTN7NkC5OC=>
MCF7 NIjBW49HfW6ldHnvckBCe3OjeR?= MV6xNEBvVQ>? M4rwO|k3KGh? MoH0[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> MWGyNVM4QDN|Mx?=
MDA-MB-231 M{S3TGZ2dmO2aX;uJGF{e2G7 NFjxc4YyOCCwTR?= NYTnNGdTQTZiaB?= MWDkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb39CpC=> NYC4VnY4OjF|N{izN|M>
SK-BR-3 MWrGeY5kfGmxbjDBd5NigQ>? NIG4NoEyOCCwTR?= MlTIPVYhcA>? MXLkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb39CpC=> MkTKNlE{Pzh|M{O=
MCF-7 NYHMNINjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv3VlIyODBibl2= NHvY[m84Oi97NjDo M2XFOoNifXOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NX3FWVZsOjF{OUm4OlI>
MMQ M2\N[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnSNE4xODhvNkK1JI5O NX7kcnVJPzJiaB?= M1POOolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NF\PUZgzODdyMEe1OS=>
MMQ MnvISpVv[3Srb36gRZN{[Xl? MliwNE4xODhvNkK1JI5O NIiyW2Q4OiCq MojEbY5pcWKrdIOgVHJNKHOnY4LleIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHSyfGYzODdyMEe1OS=>
MMQ MnPRSpVv[3Srb36gRZN{[Xl? MUSwMlA1NTZ{NTDuUS=> MWi3NkBp M{XiR4lvcGmkaYTzJGVT|rFiZYjwdoV{e2mxbh?= NUOydJRIOjB5MEC3OVU>
MMQ M3uyc2Z2dmO2aX;uJGF{e2G7 NWjJPFkzOC5yND22NlUhdk1? NX60fZp4PzJiaB?= MnKxeZBz\We3bHH0[ZMhXEeIzsKzJIFv\CCWR1dOtnJKUSCneIDy[ZN{cW:w NYHO[phDOjB5MEC3OVU>

... Click to View More Cell Line Experimental Data

In vivo Fulvestrant is devoid of uterotropic activity, and when co-administered with estradiol, it effectively blocks the uterotropic action of estradiol with ED50 of 0.06 mg/kg/day s.c. in immature female rats. A single s.c. injection of 5 mg of Fulvestrant suspension blocks completely the growth of MCF-7 xenografts. The growth of transplants of the BrlO human breast tumor is also suppressed effectively by 10 μM Fulvestrant. [1] Fulvestrant (10 mg/rat, s.c.) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. [7] Fulvestrant also displays anti-angiogenesis in the chick egg chorioallantoic membrane. [8]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MCF-7 breast cancer cells
  • Concentrations: 2.9 nM
  • Incubation Time: 5 days
  • Method: MCF-7 cells are cultured in multiwell plates (24-well, seeding density 4 × 104) in minimal essential medium containing phenol red, insulin (10 μg/mL), and 5% charcoal-stripped fetal calf serum without additional estradiol. Fulvestrant and/or estradiol are added in fresh medium 2 days after seeding. Cultures are maintained for 5 days with one further medium change and growth is assessed by measurement of total cell protein at the beginning and end of treatment and compared with that of controls treated with ethanol (0.1%) alone.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: The human breast cancer xenografts MCF-7 in nude mice
  • Formulation: 50 mg/mL in arachis oil
  • Dosages: 5 mg/mouse
  • Administration: s.c. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (164.8 mM)
Ethanol 100 mg/mL warmed (164.8 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5% DMSO+95% Corn oil
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 606.77
Formula

C32H47F5O3S

CAS No. 129453-61-8
Storage powder
Synonyms ICI-182780, ZD 9238

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01797120 Active, not recruiting Metastatic Breast Cancer PrECOG, LLC.|Novartis May 31, 2013 Phase 2
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT03024580 Not yet recruiting Breast Neoplasm Instituto Nacional de Cancer, Brazil|Cancer Research UK Cambridge Institute March 2017 Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3
NCT02983604 Recruiting Advanced Estrogen Receptor Positive HER2- Breast Cancer Gilead Sciences January 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • Answer:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

Related Estrogen/progestogen Receptor Products

Tags: buy Fulvestrant | Fulvestrant ic50 | Fulvestrant price | Fulvestrant cost | Fulvestrant solubility dmso | Fulvestrant purchase | Fulvestrant manufacturer | Fulvestrant research buy | Fulvestrant order | Fulvestrant mouse | Fulvestrant chemical structure | Fulvestrant mw | Fulvestrant molecular weight | Fulvestrant datasheet | Fulvestrant supplier | Fulvestrant in vitro | Fulvestrant cell line | Fulvestrant concentration | Fulvestrant nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID